Novartis Starts 2020 a Step Ahead of Other Big Pharmas with the Most Newly Approved Drugs

The Food and Drug Administration approved five new Novartis (NYSE: NVS) drugs last year, the most of any big pharma in 2019. Moreover, those compounds address five different disease areas, offering the company opportunities to tackle a variety of markets.